UNLIMITED TURBO BULL - MODERNA | Market Closed - Euronext Paris 17:30:01 30/04/2024 BST | ||
| 5.46 EUR | +1.11% |
|
| 1 month | +8.76% | ||
| 3 months | +16.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 5.46 | +1.11% | 61 |
| 29/04/24 | 5.4 | +7.14% | 62 |
| 26/04/24 | 5.04 | +4.89% | 74 |
| 25/04/24 | 4.805 | -4.47% | 85 |
| 24/04/24 | 5.03 | -.--% | 64 |
Real-time Euronext Paris
Last update April 30, 2024 at 05:30 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 7Z34S | |
| ISIN | DE000SB43627 |
| Date issued | 03/09/2020 |
| Strike | 53.67 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.94 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.08 € |
|---|---|
| Lowest since issue | 1.25 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
111.5
USD
Average target price
134.3
USD
Spread / Average Target
+20.49%
- Stock Market
- Certificates
- 7Z34S Certificat
